Similar Posts
Kymera Therapeutics' (KYMR) "Buy" Rating Reiterated at Truist Financial
Truist Financial restated a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday. Source link
Jubilant Ingrevia: Betting on CDMO
Source: Investor Presentation of Jubilant Ingrevia Ltd Source link
New Home Sales Decrease to 634,000 Annual Rate in April
by Calculated Risk on 5/23/2024 01:55:00 PM Today, in the Calculated Risk Real Estate Newsletter: New Home Sales Decrease to 634,000 Annual Rate in April Brief excerpt: Note: there were some seasonal revisions back to 2019, and significant changes to house prices and price distribution in this release. The Census Bureau reports New Home Sales…
Linkfest: 14 January, 2026
Some stuff I am reading today morning: US steps up for action in Iran (WSJ) Iran’s currency has collapsed (Climateer) US-China talks could get derailed due to Iran (CNBC) Iran unrest hits Indian basmati rice exports (Rediff) GoI against 10 min delivery promise (Forbes) Illusion of calm in Indian markets (ML) Sector: Insurance Stocks (FE)…
Long Haul Gold – Fat Tail Daily
More and more investors are jumping on the Gold Express. MarketWatch: Last week, something interesting happened on CNBC. Host Scott Wapner was interviewing Jeffrey Gundlach — they call him the Bond King. Wapner lobbed him a softball about portfolio allocation. “Really? One quarter of one’s portfolio in gold?” “Yeah,” Gundlach said. Then he called it…
